Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2025 Feb 3;22(2):e1004536. doi: 10.1371/journal.pmed.1004536

Risk of placenta previa in assisted reproductive technology: A Nordic population study with sibling analyses

Eirik Landsverk 1,*, Kjersti Westvik-Johari 1,2, Ulla-Britt Wennerholm 3, Christina Bergh 3, Frederik Kyhl 4, Anne Lærke Spangmose 4, Ditte Vassard 4, Anja Pinborg 4,5, Kristiina Rönö 6, Mika Gissler 7,8, Sindre Hoff Petersen 1, Signe Opdahl 1
Editor: Jenny E Myers9
PMCID: PMC11835333  PMID: 39899615

Abstract

Background

A higher risk of placenta previa after assisted reproductive technology (ART) is well established. The underlying mechanisms are poorly understood, but may relate to embryo culture duration, cryopreservation, and cause of infertility. Within-mother analyses, where each woman is her own control (i.e., sibling design), help disentangle treatment contributions from maternal confounders that are stable between pregnancies. We aimed to investigate the risk of placenta previa in pregnancies achieved after ART according to embryo culture duration, cryopreservation, and infertility factors while accounting for stable maternal factors using within-mother analyses.

Methods and findings

We used linked nationwide registry data from Denmark (1994 to 2014), Finland (1990 to 2014), Norway (1988 to 2015), and Sweden (1988 to 2015). All women who gave their first birth during the study period at age 20 years or older were eligible and contributed up to 4 deliveries (singleton or multifetal) occurring between 22 and 44 weeks of gestation, excluding deliveries where maternal age exceeded 45 years. We used multilevel logistic regression to compare risk of placenta previa after ART (n = 139,694 deliveries) versus natural conception (n = 5,614,512 deliveries), both at the population level and within mothers, adjusting for year of delivery, maternal age, parity, and country. We categorized ART according to culture duration, embryo cryopreservation, and infertility factors. Population level risk of placenta previa was higher for ART versus natural conception (odds ratio [OR], 4.16; 95% confidence interval [CI], 3.96–4.37). Controlling for stable maternal factors, the association attenuated, but risk remained higher for ART versus natural conception (OR within mothers, 2.64; 95% CI, 2.31–3.02). Compared to naturally conceived, a larger difference in risk was seen for pregnancies from fresh embryos than for pregnancies from frozen embryos. Further categorization by culture duration showed the largest risk difference after fresh blastocyst transfer, and the smallest after frozen cleavage stage embryo transfer, which persisted in sensitivity analyses (including restriction to singletons). When stratified according to infertility factors at the population level, women with endometriosis conceiving by ART had the highest risk of placenta previa (OR, 9.35; 95% CI, 8.50–10.29), whereas women with polycystic ovary syndrome (PCOS) conceiving by ART had the lowest risk (OR, 1.52; 95% CI, 1.12–2.09), compared to natural conception. Within mothers, we found a higher risk of placenta previa after ART compared to natural conception for women with endometriosis (OR, 2.08; 95% CI, 1.50–2.90), but not for women with PCOS (OR, 0.88; 95% CI, 0.41–1.89 [unadjusted due to sparse data]). However, within-mother analyses are restricted to multiparous women with deliveries after different conception methods. Therefore, findings from these analyses might not generalize to all women undergoing ART.

Conclusions

The risk of placenta previa in pregnancies conceived by ART differed by embryo culture duration, cryopreservation, and underlying infertility. The highest risk was seen after fresh embryo transfer and especially fresh blastocyst transfer. Women with endometriosis had a higher risk than women with other infertility factors, and within mothers, their risk was higher after ART than after natural conception. Identifying the responsible mechanisms might provide opportunities for prevention.


Erik Landsverk and colleagues investigate the mechanisms associated with the elevated risk of placenta previa after assisted reproductive technology, while controlling for maternal confounders by using a sibling design.

Author summary

Why was this study done?

  • Studies indicate risk of placenta previa in assisted reproductive technology (ART) differs by type of ART method and underlying infertility.

  • We aimed to increase our understanding of these factors’ contributions by improved confounding control using within-mother (sibling) analyses.

What did the researchers do and find?

  • Using each mother as her own control, we found the highest risk of placenta previa after fresh blastocyst transfer.

  • In addition, we found a markedly higher risk among women with endometriosis who conceived after assisted reproductive technology, which remained doubled compared to natural conception after controlling for maternal factors through within-mother analyses.

What do these findings mean?

  • This study strengthens evidence that treatment and maternal factors may both contribute to risk of placenta previa in assisted reproductive technology.

  • Further insights into the mechanisms responsible might lead to development of safer ART methods.

  • Although within-mother analyses are less prone to confounding from stable maternal factors, the findings of these analyses require that women have several births; hence, results might not apply to all women using ART.

Introduction

The use of assisted reproductive technology (ART) is increasing worldwide [1]. This can be attributed to increasing success rates and availability of ART, and postponement of parenthood to an age with lower fecundity [2,3]. Compared to natural conception (NC), ART is associated with higher risk of pregnancy complications such as hypertensive disorder of pregnancy, gestational diabetes mellitus, and placenta previa [4–6], as well as adverse perinatal outcomes including small for gestational age, preterm birth, and perinatal death [7].

In Europe, more than 200,000 children are born after ART each year (constituting 3% of the total birth cohorts), and transfer of single embryos has greatly reduced multifetal gestations and hence perinatal complications in ART-conceived pregnancies [3,8,9]. In contrast, the risk of placenta previa after ART has increased over time in the Nordic countries [10], which is concerning as placenta previa is associated with complications for both the mother and child [11–17].

Previous studies have linked both fresh embryo transfer (fresh-ET) and blastocyst transfer, and the combination of the two, with increased risk of placenta previa [18–26], but these findings are inconsistent [27,28]. Differences in underlying infertility might explain some of the discrepancies between previous studies [18,29,30]. Separating the contributions from underlying infertility and ART may be possible with a within-mother design, i.e., sibling design [31,32].

In a large study population, we investigated the risk of placenta previa according to embryo culture duration (i.e., cleavage stage embryo transfer versus blastocyst stage embryo transfer), cryopreservation, and infertility factors, accounting for maternal factors using within-mother analyses.

Materials and methods

This study is reported as per the Reporting of Studies Conducted using Observational Routinely-Collected Data (RECORD) guideline (S1 Checklist). All analyses were planned a priori as outlined in S1 Study Protocol.

Data sources and variables

We used data from the Committee of Nordic Assisted Reproductive Technology and Safety (CoNARTaS) cohort, which comprises all deliveries in the Medical Birth Registries (MBRs) in Denmark, Finland, Norway, and Sweden since the start of national ART registration. The MBRs collect information on all deliveries in each country. The mothers’ unique national identity number was pseudonymized before individual data linkage between the MBRs and other national health registries, described in more detail in a previous publication by our research group [33].

The exposure was conception by ART, defined as fertilization outside the female body, i.e., fertilization with in vitro fertilization (IVF) or intracytoplasmic sperm injection [34]. ART-conception was identified through ART registries in Denmark and Sweden, and MBRs in Norway and Finland [33]. Pregnancies after ovulation induction and insemination were categorized as naturally conceived together with pregnancies not registered as ART-conceived. Danish, Norwegian, and Swedish ART data could be further categorized as cleavage stage embryo transfer (culture duration 2 to 3 days) or blastocyst transfer (culture duration 5 to 6 days), and as fresh-ET or frozen thawed embryo transfer (frozen-ET).

The outcome was placenta previa, identified from the MBRs in Finland, Norway, and Sweden, and the National Patient Registries of Denmark and Finland (S1 Table). Using these registries, we could not differentiate between total, partial, or marginal placenta previa, or low-lying placenta (<2 cm from the internal os). We only included diagnoses during the third trimester or within 1 month before delivery from the National Patient Registries because most low-lying placentas in the second trimester resolve in the third trimester [35]. In the Nordic countries, placenta previa is usually discovered at second trimester routine ultrasonography, and follow-up is normally performed in week 32 to 34 to evaluate whether it has resolved [36–38].

Infertility factors (i.e., diagnoses associated with infertility) were identified using the National Patient Registries of each country, supplemented with information from the national IVF registry in Denmark, and the Medical Birth Registry of Norway (S2 and S3 Tables). We assigned each woman to only one of these factors during the study period. Factors more strongly associated with the risk of placenta previa [18,29,30], and factors with low prevalence, were given priority in this order: uterine factors, endometriosis, polycystic ovary syndrome (PCOS), male-factor infertility only, and other infertility factors (including unspecified female infertility and unexplained infertility).

Study population

The study period was defined as 1994 to 2014 in Denmark, 1990 to 2014 in Finland, and 1988 to 2015 in Norway and Sweden. Only deliveries by women whose first delivery occurred during the study period at age ≥20 years were defined as eligible (Fig 1). This was done to ensure sufficient overlap in year of delivery, maternal age, and parity between ART and NC [39]. For these women, up to the first 4 deliveries were included (parity 0–3), excluding deliveries at maternal age >45 years. In addition, deliveries with extreme (<22 or >44 weeks) or missing gestational age were excluded. We included multifetal pregnancies because this does not seem to be a clear risk factor of placenta previa [9,10,30,40]. ART-conceived pregnancies after gamete donation and/or with preimplantation genetic testing were also included. Sample 1 included 5,754,206 deliveries in all 4 countries combined. Among these, 139,694 were from ART-conceived pregnancies, and 42,792 women gave birth after both ART and NC during the study period (Fig 1).

Fig 1. Flow chart of study population showing eligibility, exclusion criteria and numbers, and number of exposed and unexposed in the 3 analyses samples.

Fig 1

ART, assisted reproductive technology; fresh-ET, fresh embryo transfer; frozen-ET, frozen embryo transfer; fresh-CT, fresh cleavage stage embryo transfer; fresh-BT, fresh blastocyst transfer; frozen-CT, frozen cleavage stage embryo transfer; frozen-BT, frozen blastocyst transfer.

In sample 2, ART-conceived pregnancies with missing cryopreservation status were excluded. To create sample 3, ART-conceived pregnancies with missing culture duration were excluded, leaving 94,631 deliveries after ART for analyses on combinations of culture duration and cryopreservation (Fig 1). We also excluded pregnancies after NC from Finland in samples 2 and 3 as there was no information on culture duration or cryopreservation among ART-conceived pregnancies in Finland.

Statistical analyses

We estimated adjusted odds ratios (aORs) for placenta previa at the population level and within mothers using multilevel logistic regression with deliveries nested within mothers (using the “xtlogit” command in Stata with maternal identity codes specified as clusters). This hierarchical approach adjusts for clustering of pregnancies by the same mother. Population-level associations were estimated in random intercept models using the full analysis samples, where each mother contributed 1 to 4 deliveries (multifetal pregnancy counting as 1 delivery). Within mother associations were estimated using a fixed intercept model [41], where each mother contributed 2 to 4 deliveries. In the latter model, deliveries contribute to the final exposure-outcome estimate only if both the exposure and outcome differ between pregnancies by the same mother. As a sensitivity analysis, we restricted both models to only include the first 2 consecutive deliveries by each mother. Available data on factors known to influence the probability of ART conception and the risk of placenta previa were included as covariates in the regression models; year of delivery (categorical: 1988–1996, 1997–2001, 2002–2006, 2007–2011, 2012–2015), maternal age (categorical: 20–24, 25–29, 30–34, 35–39, 40–45), parity (categorical: 0, 1, 2, 3), and country.

We used all NC pregnancies as the reference in population level analyses of infertility factors. Within mothers, we performed separate analyses for each infertility factor, restricting analyses to women assigned to that factor.

In sample 2, we examined whether risk of placenta previa within mothers was driven by certain combinations of parity and conception method with ART categorized as either fresh-ET or frozen-ET. Specifically, we repeated the multilevel logistic regression at the population level with an interaction term between parity and the resulting 9 combinations of conception methods for the mothers’ first and second delivery and obtained predicted risks of placenta previa using postestimation commands. We also did a series of other sensitivity analyses to test the robustness of the results, some of which are described in more detail in S1 Text.

Finally, to assess the clinical severity of placenta previa, we compared other pregnancy outcomes (gestational age, birthweight, and cesarean section) between deliveries with and without placenta previa according to conception method and plurality.

We used Stata 18 (Statacorp LLC, Texas, United States of America) for all statistical analyses.

Ethics

In Norway, the study was approved by the Regional Committees for Medical and Health Research Ethics (REK 2010/1909). In Sweden, the study was approved by the Ethical committee in Gothenburg (Dnr 214–12, T422-12, T516-15, T233-16, T300-17, T1144-17, T121-18). In Denmark and Finland, ethical approval is not required for research only based on registry data. In accordance with legal regulations of the participating countries, written consent from participants is not required when using registry data in Denmark and Finland, and the ethical committees gave exemption from obtaining consent in Norway and Sweden.

Results

Background characteristics differed between pregnancies after ART and NC (Table 1). The number of deliveries after ART increased over the study period. Women who conceived by ART were on average 4 years older, had lower parity and less frequently smoked during pregnancy, compared to naturally conceiving women. In addition, twin pregnancies were more common after ART than NC (14.0% versus 1.3%).

Table 1. Description of the study population in sample 1.

ART NC
Total number of pregnancies, n 139,694 5,614,512
Country, n (%)
  Denmark 35,365 (25.3) 1,001,886 (17.8)
  Finland 23,835 (17.1) 1,111,804 (19.8)
  Norway 26,805 (19.2) 1,217,113 (21.7)
  Sweden 53,689 (38.4) 2,283,709 (40.7)
Year of birth, n (%)
  1988–1996 11,624 (8.3) 1,295,414 (23.1)
  1997–2001 22,371 (16.0) 1,046,979 (18.7)
  2002–2006 30,251 (21.7) 1,165,294 (20.8)
  2007–2011 41,727 (29.9) 1,234,664 (22.0)
  2012–2015 33,721 (24.1) 872,161 (15.5)
Mean maternal age (SD) 33.7 (4.2) 29.6 (4.8)
Parity, n (%)
  0 100,857 (72.2) 2,862,509 (51.0)
  1 33,881 (24.3) 1,998,172 (35.6)
  2 4,251 (3.0) 620,801 (11.1)
  3 705 (0.5) 133,030 (2.4)
Smokinga, n (%)
  Yes 7,198 (5.3) 610,606 (11.8)
  No 120,830 (89.2) 4,280,132 (82.5)
  Missingb 7,362 (5.4) 299,460 (5.8)
Maternal BMIc (kg/m2), mean (SD) 24.2 (4.1) 24.2 (4.5)
  Missingb, n (%) 14,210 (13.4) 538,828 (14.5)
Infertility factors
  Uterine factord 1,517 (1.1) NA
  Endometriosise 16,205 (11.6) NA
  PCOSf 7,051 (5.1) NA
  Male factors onlyg 10,222 (7.3) NA
  Other infertility factorsh 97,401 (70.0) NA
  Missingi 7,298 (5.2) NA
Plurality, n (%)
  Singleton 119,591 (85.6) 5,540,830 (98.7)
  Twin 19,513 (14.0) 72,504 (1.3)
  Triplet or higher 590 (0.4) 1,178 (0.0)

a Smoking was recorded from 1999 in Norway and prior to our study period in Denmark, Finland, and Sweden.

b Missing during registration period.

c BMI was recorded from 2007 in Norway, 2004 in Denmark and Finland, and prior to our study period in Sweden.

d Pregnancies by women once diagnosed with female infertility due to uterine factors.

e Pregnancies by women once diagnosed with endometriosis without any diagnosis of female infertility due to uterine factors.

f Pregnancies by women once diagnosed with polycystic ovary syndrome, without any diagnosis of female infertility due to uterine factors nor endometriosis.

g Pregnancies by women once diagnosed with infertility due to male factors, without any diagnosis of infertility due to female factors.

h Pregnancies by women with other infertility factors than uterine factors, endometriosis, PCOS, and male factors only. This category also includes pregnancies by women with unspecified female infertility and unexplained infertility.

i Pregnancies by women missing any diagnosis code associated with infertility.

ART, assisted reproductive technology; NC, natural conception, NA, not applicable; PCOS, polycystic ovary syndrome.

For ART versus NC at the population level, aOR of placenta previa was 4.16 (95% confidence interval [CI], 3.96–4.37). Comparisons within mothers who delivered after both ART and NC also showed a clearly higher risk after ART, although the point estimate was lower than at the population level (aOR, 2.64; 95% CI, 2.31–3.02). At the population level, risk was higher after fresh-ET (aOR, 4.69; 95% CI, 4.41–4.98) than after frozen-ET (aOR, 2.71; 95% CI, 2.35–3.13), using NC as reference. When further categorizing fresh-ET and frozen-ET according to culture duration, population-level risk was higher for all treatment combinations compared to NC (Table 2), with the highest risk after fresh blastocyst transfer (fresh-BT, aOR, 11.51; 95% CI, 9.75–13.57). Within mothers, risk estimates attenuated to some extent, but remained higher for all treatment combinations except frozen cleavage stage embryo transfer (frozen-CT, Table 2).

Table 2. Observed risk and adjusted odds ratio of placenta previa at the population level and within mothers according to conception method and sample.

Population level Within mothers
N Observed risk Adjusted odds ratioa (95% CI) N b Observed riskc Adjusted odds ratiod (95% CI)
Sample 1
  NC 5,614,512 3.1/1,000 1 (ref) 51,521 7.3/1,000 1 (ref)
  ART 139,694 17.2/1,000 4.16 (3.96 to 4.37) 44,843 17.8/1,000 2.64 (2.31 to 3.02)
Sample 2
  NC 4,502,708 2.8/1,000 1 (ref) 39,237 6.4/1,000 1 (ref)
  Fresh-ET 93,078 17.4/1,000 4.69 (4.41 to 4.98) 34,810 18.3/1,000 3.31 (2.81 to 3.91)
  Frozen-ET 19,851 11.1/1,000 2.71 (2.35 to 3.13) 10,724 10.4/1,000 1.59 (1.19 to 2.13)
Sample 3
  NC 4,502,708 2.8/1,000 1 (ref) 32,182 6.6/1,000 1 (ref)
  Fresh-CT 72,878 16.5/1,000 4.24 (3.96 to 4.54) 27,497 17.3/1,000 3.07 (2.55 to 3.69)
  Fresh-BT 4,882 41.0/1,000 11.51 (9.75 to 13.57) 2401 40.0/1,000 7.80 (4.59 to 13.27)
  Frozen-CT 12,971 9.7/1,000 2.33 (1.93 to 2.80) 7303 7.9/1,000 1.20 (0.83 to 1.75)
  Frozen-BT 3,900 15.6/1,000 4.04 (3.07 to 5.31) 1768 19.8/1,000 3.13 (1.71 to 5.73)

a Adjusted for year of delivery (categorical: 1988–1996, 1997–2001, 2002–2006, 2007–2011, 2012–2015), maternal age (categorical: 20–24, 25–29, 30–34, 35–39, 40–45), parity (categorical: 0, 1, 2, 3), and country.

b Total number of pregnancies from mothers with at least 2 different conception methods.

c Observed risk in pregnancies from mothers with at least 2 different conception methods.

d Adjusted for year of delivery, maternal age, and parity (country is constant within mothers and therefore not included as a covariate in these analyses). Estimated by logistic regression (fixed intercept model) on all pregnancies in each sample.

ART, assisted reproductive technology; CI, confidence interval; fresh-ET, fresh embryo transfer; frozen-ET, frozen embryo transfer; fresh-CT, fresh cleavage stage embryo transfer; fresh-BT, fresh blastocyst transfer; frozen-CT, frozen cleavage stage embryo transfer; frozen-BT, frozen blastocyst transfer; NC, natural conception.

At the population level, ART-conception was associated with higher risk of placenta previa compared to NC for all infertility factors (Table 3), ranging from highest among women with endometriosis (aOR, 9.35; 95% CI, 8.50–10.29) to lowest among women with PCOS (aOR, 1.52; 95% CI, 1.12–2.09). Within mothers, the associations attenuated compared to the population level, but risk remained higher in ART versus NC for all infertility factors (Table 3), except for PCOS (odds ratio, 0.88; 95% CI, 0.41–1.89 [unadjusted due to sparse data]). For women with endometriosis, aOR was 2.08 (95% CI, 1.50–2.90) for ART versus NC within mothers. Giving endometriosis and PCOS first priority in the hierarchy of infertility factors, we found similar results both for endometriosis (population level aOR, 9.31; 95% CI, 8.47–10.24; aOR within mothers, 2.10; 95% CI, 1.51–2.92) and for PCOS (population-level aOR, 1.89; 95% CI, 1.44–2.48; OR within mothers, 0.82; 95% CI, 0.41–1.65 [unadjusted due to sparse data]).

Table 3. Observed risk and adjusted odds ratio of placenta previa at the population level and within mothers according to conception method and infertility factor in sample 1.

Population levela Within mothersb
N Observed risk Adjusted odds ratioc (95% CI) N d Observed riske Adjusted odds ratiof (95% CI)
Uterine factorsg
  NC 5,614,512 3.1/1,000 1 (ref) 472 6.4/1,000 1 (ref)
  ART 1517 18.5/1,000 3.76 (2.51 to 5.65) 430 20.9/1,000 3.06 (0.82 to 11.41)h
Endometriosisi
  NC 5,614,512 3.1/1,000 1 (ref) 5481 15.5/1,000 1 (ref)
  ART 16,205 37.3/1,000 9.35 (8.50 to 10.29) 4983 30.7/1,000 2.08 (1.50 to 2.90)
PCOSj
  NC 5,614,512 3.1/1,000 1 (ref) 2434 6.6/1,000 1 (ref)
  ART 7,051 6.1/1,000 1.53 (1.12 to 2.09) 2159 5.6/1,000 0.88 (0.41 to 1.89)h
Male factors onlyk
  NC 5,614,512 3.1/1,000 1 (ref) 3532 4.8/1,000 1 (ref)
  ART 10,222 11.3/1,000 3.04 (2.50 to 3.70) 3110 13.5/1,000 2.91 (1.64 to 5.17)h
Other infertility factorsl
  NC 5,614,512 3.1/1,000 1 (ref) 39,723 6.4/1,000 1 (ref)
  ART 104,699 15.4/1,000 3.49 (3.30 to 3.69) 34,377 17.0/1,000 2.76 (2.31 to 3.29)

a At the population level, infertility factor was only defined for pregnancies after ART.

b Within mothers, infertility factor was only defined for women with an ART conception during the study period.

c Adjusted for year of delivery (categorical: 1988–1996, 1997–2001, 2002–2006, 2007–2011, 2012–2015), maternal age (categorical: 20–24, 25–29, 30–34, 35–39, 40–45), parity (categorical: 0, 1, 2, 3), and country.

d Total number of pregnancies from mothers with pregnancies after both NC and ART during the study period.

e Observed risk in pregnancies from mothers with pregnancies after both NC and ART during the study period.

f Adjusted for year of delivery (categorical: 1988–1996, 1997–2001, 2002–2006, 2007–2011, 2012–2015), maternal age (categorical: 20–24, 25–29, 30–34, 35–39, 40–45), and parity (categorical: 0, 1, 2, 3). Country is constant within mothers and therefore not included as a covariate in these analyses. Estimated by logistic regression (fixed intercept model) on all pregnancies in each category of infertility factor.

g Pregnancies by women once diagnosed with female infertility due to uterine factors.

h The odds ratios comparing ART vs. NC within mothers in women with uterine factors, PCOS, and male factors only are unadjusted due to sparse data.

i Pregnancies by women once diagnosed with endometriosis without any diagnosis of female infertility due to uterine factors.

j Pregnancies by women once diagnosed with polycystic ovary syndrome, without any diagnosis of female infertility due to uterine factors nor endometriosis.

k Pregnancies by women once diagnosed with infertility due to male factors, without any diagnosis of infertility due to female factors.

l Pregnancies by women with other infertility factors than uterine factors, endometriosis, PCOS, and male factors only. This category also includes pregnancies by women with unspecified female infertility, unexplained infertility, and missing any diagnosis code associated with infertility.

ART, assisted reproductive technology; CI, confidence interval; NC, natural conception; PCOS, polycystic ovary syndrome.

The risk of placenta previa in the second delivery was highest after fresh-ET, intermediate after frozen-ET, and lowest after NC when stratified according to conception method in the first delivery (Fig 2). Notably, the risk increased between first and second delivery for all combinations of conception method, except when fresh-ET was followed by frozen-ET or NC, where the risk was lower in the second delivery compared to the first (Fig 2).

Fig 2. Predicted risk of placenta previa in the 2 first deliveries according conception methods in sample 2.

Fig 2

Frozen-ET, frozen embryo transfer; fresh-ET, fresh embryo transfer; NC, natural conception. We calculated predicted risk of placenta previa using multilevel logistic regression at the population level and marginal standardization (“margins” command in Stata [StataCorp, College Station, TX]). We included the following covariates in the regression model: parity (0, 1), conception methods for the mothers’ first and second delivery (categorical: NC–NC, NC–fresh-ET, NC–frozen-ET, fresh-ET–NC, fresh-ET–fresh-ET, fresh-ET–frozen-ET, frozen-ET–NC, frozen-ET–fresh-ET, frozen-ET–frozen-ET), year of delivery (categorical: 1988–1996, 1997–2001, 2002–2006, 2007–2011, 2012–2015), maternal age (categorical: 20–24, 25–29, 30–34, 35–39, 40–45), and country. We added an interaction term between parity and conception methods for the mothers’ first and second delivery to allow the slope of the lines to differ.

All sensitivity analyses were consistent with the main results. When stratified on characteristics of the first pregnancy (conception method and cesarean section/placenta previa), risk of placenta previa in the second pregnancy was consistently higher in ART-conceived pregnancies compared to NC (S4 and S5 Tables). Associations between embryo culture duration, cryopreservation, and placenta previa were also consistent across sensitivity analyses (Fig 3). Although results for fresh-BT and frozen blastocyst transfer (frozen-BT) attenuated somewhat within mothers when restricting ART-conceived pregnancies to fertilization with IVF (i.e., without intracytoplasmic sperm injection), risk still tended to be higher after fresh-BT than after other combinations of culture duration and cryopreservation status in this subpopulation (Fig 3).

Fig 3. Adjusted odds ratio of placenta previa after (A) fresh-CT, (B) fresh-BT, (C) frozen-CT, and (D) frozen-BT compared to NC in sample 3, at the population level and within mothers.

Fig 3

Fresh-CT, fresh cleavage stage embryo transfer; NC, natural conception; fresh-BT, fresh blastocyst transfer; frozen-CT, frozen cleavage stage embryo transfer; frozen-BT, frozen blastocyst transfer. Adjusted for year of delivery (categorical: 1988–1996, 1997–2001, 2002–2006, 2007–2011, 2012–2015), maternal age (categorical: 20–24, 25–29, 30–34, 35–39, 40–45), parity (categorical: 0, 1, 2, 3), and country (only included in analyses at the population level because it is constant within mothers). Analyses in “Smoking” are additionally adjusted for smoking status in the subpopulation where this information was available. In “C-section” the outcome of placenta previa is restricted to pregnancies delivered by cesarean section, whereas “Full siblings,” “First two,” “<3 years,” “SET,” “IVF,” and “Singletons” refer to restriction of analyses to full siblings (i.e., same mother and father), each mothers’ first 2 consecutive deliveries, only consecutive deliveries less than 3 years apart, single embryo transfer (using all deliveries after NC as reference), in vitro fertilization (using all deliveries after NC as reference), and singleton pregnancies, respectively.

ART-conceived singleton pregnancies with placenta previa had a shorter mean gestational age (259.0 versus 276.9 days), a higher rate of preterm birth (36.3% versus 7.5%), and a lower mean birthweight (2,986 versus 3,447 g). However, they exhibited similar mean birthweight z-scores and comparable proportions of small and large for gestational age compared to ART-conceived singleton pregnancies without placenta previa (S6 Table). A similar trend of reduced birthweight and gestational age was observed in naturally conceived pregnancies with placenta previa compared to those without, for both singleton and twin pregnancies. This pattern was also evident in ART-conceived twin pregnancies with placenta previa compared to those without (S6 Table).

Discussion

The increased risk of placenta previa in ART-conceived pregnancies differed by embryo culture duration and cryopreservation, both at the population level and within mothers, with a higher risk after fresh-ET, and especially fresh-BT. Estimates attenuated from population level to within mothers, suggesting stable maternal factors contribute to the increased risk. This was further supported by large differences in risk according to infertility factors, where women with ART-conception and endometriosis had the highest risk of placenta previa. Their risk after ART-conception remained higher in within-mother analyses, suggesting that stable maternal factors alone do not fully explain the increased risk associated with ART.

In line with our results, Spangmose and colleagues, Korosec and colleagues, Volodarsky-Perel and colleagues, and Cirillo and colleagues reported risks of 4.1%, 4.0%, 3.5%, and 4.3%, respectively, of placenta previa after fresh-BT, from a total of 4,601, 802, 425, and 202 pregnancies, respectively [23–26]. The study by Spangmose and colleagues is also based on the CoNARTaS cohort [23]. We shed new light on those findings by controlling for stable maternal factors and by improving our understanding of the potential contribution from different infertility factors.

A nationwide Japanese study of single embryo transfers (n = 48,158) showed no clear differences across combinations of culture duration and cryopreservation but had an appreciably lower risk of placenta previa after ART-conception overall (0.7% to 0.9%) than in our study [27].

Endometriosis was strongly associated with placenta previa in ART-conceived pregnancies, consistent with previous comparisons of ART-conceiving women with endometriosis to either ART-conceiving women without endometriosis [18,30,41–43], or women who conceived naturally with or without endometriosis [29,42]. We elaborate these observations by using within-mother analyses to disentangle the contribution of ART from that of endometriosis. Our results indicate that ART is associated with a doubled odds of placenta previa in women with endometriosis, from an already higher baseline risk than among women with other infertility factors.

In ART, PCOS was associated with lower risk of placenta previa than other infertility factors. This is consistent with previous studies comparing women using ART for ovulation disorders to women with NC [29] and to women without ovulation disorders using ART [18,30]. In contrast to previous studies, we studied PCOS instead of ovulation disorders, because the latter also includes poor ovarian reserve due to advanced maternal age, which makes interpretation more challenging.

Several mechanisms for a higher risk of placenta previa after ART-conception have been suggested. One hypothesis is that the position of the catheter during embryo transfer might play a role [44], supported by observations that transfer site corresponds to implantation site in 80% of transfers [45]. Another hypothesis is that the catheter sometimes causes uterine contractions when passing through the cervix, which may displace the embryo [46]. Enhanced uterine peristalsis has also been hypothesized to play a role in the higher risk of previa in women with endometriosis [47].

Fresh-ET is associated with higher levels of estradiol and progesterone at the time of embryo transfer compared to frozen-ET, as a result of ovarian stimulation [48,49]. Increased levels of estradiol have been proposed to lower the threshold for uterine contractions in response to mechanical stimuli, which could explain the higher risk of placenta previa after fresh-ET [46]. However, a later study found no association between peak estradiol during ovarian stimulation and subsequent risk of placenta previa after fresh-ET [47]. Further, a premature rise in progesterone levels has been shown to induce premature maturation of the endometrium [49]. It seems conceivable that a longer secretory phase might make the endometrium in the lower segment of the uterus more receptive to embryo implantation in fresh-ET compared to frozen-ET and NC. This effect may be enhanced in fresh-BT as extended culture duration results in prolonged maturation of the endometrium before embryo transfer. Indeed, thicker endometrium is associated with higher risk of placenta previa after fresh-ET [47,50,51], but not after frozen-ET [52,53]. A greater number of retrieved oocytes have been associated with higher progesterone levels [54]. We had no information on progesterone levels during ovarian stimulation, but a study of deliveries after fresh-ET in Sweden between 2002 and 2015 found that retrieval of more oocytes was associated with higher risk of placenta previa in singleton pregnancies [55].

Future studies should explore the association between fresh-ET, premature rise in progesterone levels and subsequent risk of placenta previa. In addition, analyses of the risk of placenta previa according to embryo culture duration and cryopreservation in women with endometriosis, and women with other infertility factors, is warranted.

Strengths and limitations

A key strength of this study is the within-mother analyses where each woman serves as her own control [56]. In a Norwegian study population that partly overlaps with ours, Romundstad and colleagues also found higher risk of placenta previa after ART compared to NC using within-mother analyses [44]. We provide new insights by deepening our understanding of the potential roles of different ART methods and infertility factors.

Given the observational nature of this study, we cannot exclude the possibility of unknown or unmeasured confounding. While we expect within-mother analyses to be less confounded from stable maternal factors (such as cause of infertility and genetic predisposition for placenta previa), we cannot rule out confounding from non-stable maternal factors. However, we note that the risk of placenta previa was highest after fresh-ET regardless of delivery order among women who gave birth after different conception methods in their first 2 consecutive births.

We had limited data on ART treatment details, which was missing for all Finnish ART-pregnancies. Furthermore, cryopreservation and blastocyst transfers were uncommon in the first half of our study period [23,33]. Consequently, there were not enough pregnancies after fresh-BT and frozen-BT to do country-specific analyses. Instead, we included country as a categorical covariate in the regression models to adjust for differences between countries. Similarly, we did not have sufficient statistical power to explore the risk of placenta previa after fresh cleavage stage embryo transfer (fresh-CT), frozen-CT, fresh-BT, and frozen-BT according to infertility factors.

While we cannot rule out information bias from differences in data sources and registration practice of placenta previa, we expect this to be non-differential with respect to conception method. Furthermore, we assume negligible information bias from defining pregnancies after ovulation induction and insemination as natural conceptions, because these pregnancies are very few compared to the remaining background population. Moreover, beyond restricting the diagnosis of placenta previa to deliveries with cesarean section in sensitivity analysis, we could not separate a total, partial, or marginal placenta previa from a low-lying placenta. However, low-lying placentas also appear clinically relevant [57,58], and their management are similar to placenta previa [59].

The higher risk of placenta previa in women with endometriosis in our study might not reflect the risk associated with endometriosis in general, since we restricted diagnosis of endometriosis to women with delivery after ART. Of note, an ICD-code of endometriosis in the Swedish National Patient Registry showed a positive predictive value of 97.8% compared to the gold standard of reviewing patient charts [60]. Furthermore, our assignment of women to specific infertility factor groups will not always reflect the main cause of infertility, which can also be difficult to ascertain clinically [61]. We had no data on the severity or diagnostic basis of endometriosis, both of which may be associated with the risk of placenta previa [62,63].

A strength of this study was the consistency of results across a series of sensitivity analyses. The population-based design with inclusion of both singleton and multifetal pregnancies is expected to better capture the total effect of ART compared to previous studies [21–27]. ART treatment as well as the ART-treated populations continues to change, thus, there is a possibility that our findings of a higher risk of placenta previa after ART might not apply to women receiving treatment today. Although the newest data in this study were from 2015, we expect the findings to apply to contemporary treatment practices such as single embryo transfer and blastocyst culture. Fresh-BT now constitutes 18% to 21% of all Swedish embryo transfers, and frozen-BT has become far more prevalent than frozen-CT [64]. Indeed, a previous study on the CoNARTaS cohort showed a steadily increasing risk of placenta previa after ART compared to NC between 1988 and 2015, which might partly be explained by a shift from cleavage stage to blastocyst embryo transfer [10]. Nevertheless, caution is needed when generalizing our findings to populations outside the Nordic countries, as no clear pattern between placenta previa, embryo culture duration and cryopreservation status was found in a large registry-based study from Japan [27]. Furthermore, results from within-mother analyses might not generalize to all women using ART, as these analyses are restricted to multiparous women with different conception methods.

Conclusions

Our study indicates that the higher risk of placenta previa after ART is associated with both treatment and maternal factors, where fresh-ET, and especially fresh-BT, was associated with an increased risk of placenta previa. Furthermore, women diagnosed with endometriosis and receiving ART seemed to be at particularly high risk, possibly due to contributions from ART. Further insights into the mechanisms responsible might lead to development of safer ART methods. Although the risk of placenta previa may not be weighted heavily when choosing the type of ART treatment, it might be considered along with the risk of other complications, especially if the alternative treatment types will not reduce the chances of achieving a pregnancy.

Supporting information

S1 Checklist. The RECORD statement—checklist of items, extended from the STROBE statement that should be reported in observational studies using routinely collected health data.

(DOCX)

pmed.1004536.s001.docx (34.3KB, docx)
S1 Table. Data sources and registration practice for placenta previa in the Nordic countries during the study period.

(DOCX)

pmed.1004536.s002.docx (20.8KB, docx)
S2 Table. Data sources and registration practice for infertility factors in the Nordic countries during the study period.

(DOCX)

pmed.1004536.s003.docx (21.9KB, docx)
S3 Table. ICD codes used for identification of infertility factors in the Nordic countries during the study period.

(DOCX)

pmed.1004536.s004.docx (20.6KB, docx)
S4 Table. Observed risk and adjusted odds ratio of placenta previa in second pregnancy according to conception method and cesarean section in first pregnancy in sample 1.

(DOCX)

pmed.1004536.s005.docx (23.2KB, docx)
S5 Table. Observed risk and adjusted odds ratio of placenta previa in second pregnancy according to conception method and placenta previa in first pregnancy in sample 1.

(DOCX)

pmed.1004536.s006.docx (23.2KB, docx)
S6 Table. Description of pregnancies with and without placenta previa according to conception method and plurality in sample 1.

(DOCX)

pmed.1004536.s007.docx (25.9KB, docx)
S1 Text. More detailed description of sensitivity analyses.

(DOCX)

pmed.1004536.s008.docx (21.8KB, docx)
S1 Study Protocol. Risk of placenta previa in assisted reproductive technology: A Nordic registry-based population study with within-sibship analyses.

(PDF)

pmed.1004536.s009.pdf (272.4KB, pdf)

Acknowledgments

We would like to thank the staff in the ART clinics and labor departments in all 4 countries for their efforts in recording the data used in this study.

Abbreviations

aOR

adjusted odds ratio

ART

assisted reproductive technology

BT

blastocyst transfer

CI

confidence interval

CT

cleavage stage embryo transfer

ET

embryo transfer

IVF

in vitro fertilization

MBR

Medical Birth Registry

NC

natural conception

OR

odds ratio

PCOS

polycystic ovary syndrome

Data Availability

Data cannot be shared publicly owing to restrictions by law. Data are available from the CoNARTaS server at Statistics Denmark, after approval by the Ethics Committees and registry keeping authorities in each country, as described in the following publication: Opdahl S, Henningsen AA, Bergh C, Gissler M, Romundstad LB, Petzold M, Tiitinen A, Wennerholm UB, Pinborg AB. Data Resource Profile: Committee of Nordic Assisted Reproductive Technology and Safety (CoNARTaS) cohort. Int J Epidemiol. 2020 Apr 1;49(2):365-366f. doi: 10.1093/ije/dyz228. Contact information for Statistics Denmark: Division of Research Services, Statistics Denmark, Sejrøgade 11, DK-2100, Copenhagen, Denmark. E-mail:forskningsservice@dst.dk. Phone: +45 39 17 31 30.

Funding Statement

This work was supported by NordForsk (71450 to SO), the Central Norway Regional Health Authorities (46045000 to SO), the Nordic Federation of Obstetrics and Gynaecology (NF13041, NF15058, NF16026 and NF17043 to UBW), and the Interreg Öresund-Kattegat-Skagerrak European Regional Development Fund (ReproUnion project, to AP & CB). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Chambers GM, Dyer S, Zegers-Hochschild F, de Mouzon J, Ishihara O, Banker M, et al. International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2014†. Hum Reprod. 2021;36:2921–2934. doi: 10.1093/humrep/deab198 [DOI] [PubMed] [Google Scholar]
  • 2.Schmidt L, Sobotka T, Bentzen JG, Nyboe Andersen A, ESHRE Reproduction and Society Task Force. Demographic and medical consequences of the postponement of parenthood. Hum Reprod Update. 2012;18:29–43. doi: 10.1093/humupd/dmr040 [DOI] [PubMed] [Google Scholar]
  • 3.Smeenk J, Wyns C, The European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE), De Geyter C, Kupka M, Bergh C, et al. ART in Europe, 2019: results generated from European registries by ESHRE†. Hum Reprod. 2023;38:2321–2338. doi: 10.1093/humrep/dead197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Karami M, Jenabi E, Fereidooni B. The association of placenta previa and assisted reproductive techniques: a meta-analysis. J Matern Fetal Neonatal Med. 2018;31:1940–1947. doi: 10.1080/14767058.2017.1332035 [DOI] [PubMed] [Google Scholar]
  • 5.Bosdou JK, Anagnostis P, Goulis DG, Lainas GT, Tarlatzis BC, Grimbizis GF, et al. Risk of gestational diabetes mellitus in women achieving singleton pregnancy spontaneously or after ART: a systematic review and meta-analysis. Hum Reprod Update. 2020;26:514–544. doi: 10.1093/humupd/dmaa011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Keukens A, van Wely M, van der Meulen C, Mochtar MH. Pre-eclampsia in pregnancies resulting from oocyte donation, natural conception or IVF: a systematic review and meta-analysis. Hum Reprod. 2022;37:586–599. doi: 10.1093/humrep/deab267 [DOI] [PubMed] [Google Scholar]
  • 7.Qin J, Liu X, Sheng X, Wang H, Gao S. Assisted reproductive technology and the risk of pregnancy-related complications and adverse pregnancy outcomes in singleton pregnancies: a meta-analysis of cohort studies. Fertil Steril. 2016;105 (73–85):e1–e6. doi: 10.1016/j.fertnstert.2015.09.007 [DOI] [PubMed] [Google Scholar]
  • 8.Henningsen AA, Gissler M, Skjaerven R, Bergh C, Tiitinen A, Romundstad LB, et al. Trends in perinatal health after assisted reproduction: a Nordic study from the CoNARTaS group. Hum Reprod. 2015;30:710–716. doi: 10.1093/humrep/deu345 [DOI] [PubMed] [Google Scholar]
  • 9.Oberg AS, VanderWeele TJ, Almqvist C, Hernandez-Diaz S. Pregnancy complications following fertility treatment-disentangling the role of multiple gestation. Int J Epidemiol. 2018;47:1333–1342. doi: 10.1093/ije/dyy103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Petersen SH, Bergh C, Gissler M, Åsvold BO, Romundstad LB, Tiitinen A, et al. Time trends in placenta-mediated pregnancy complications after assisted reproductive technology in the Nordic countries. Am J Obstet Gynecol. 2020;223:226.e1–226.e19. doi: 10.1016/j.ajog.2020.02.030 [DOI] [PubMed] [Google Scholar]
  • 11.Crane JM, Van den Hof MC, Dodds L, Armson BA, Liston R. Maternal complications with placenta previa. Am J Perinatol. 2000;17:101–105. doi: 10.1055/s-2000-9269 [DOI] [PubMed] [Google Scholar]
  • 12.Onwere C, Gurol-Urganci I, Cromwell DA, Mahmood TA, Templeton A, van der Meulen JH. Maternal morbidity associated with placenta praevia among women who had elective caesarean section. Eur J Obstet Gynecol Reprod Biol. 2011;159:62–66. doi: 10.1016/j.ejogrb.2011.07.008 [DOI] [PubMed] [Google Scholar]
  • 13.Lal AK, Hibbard JU. Placenta previa: an outcome-based cohort study in a contemporary obstetric population. Arch Gynecol Obstet. 2015;292:299–305. doi: 10.1007/s00404-015-3628-y [DOI] [PubMed] [Google Scholar]
  • 14.Fan D, Xia Q, Liu L, Wu S, Tian G, Wang W, et al. The Incidence of Postpartum Hemorrhage in Pregnant Women with Placenta Previa: A Systematic Review and Meta-Analysis. PLoS ONE. 2017;12:e0170194. doi: 10.1371/journal.pone.0170194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Gibbins KJ, Einerson BD, Varner MW, Silver RM. Placenta Previa and Maternal Hemorrhagic Morbidity. J Matern Fetal Neonatal Med. 2018;31:494–499. doi: 10.1080/14767058.2017.1289163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Salihu HM, Li Q, Rouse DJ, Alexander GR. Placenta previa: neonatal death after live births in the United States. Am J Obstet Gynecol. 2003;188:1305–1309. doi: 10.1067/mob.2003.303 [DOI] [PubMed] [Google Scholar]
  • 17.Vahanian SA, Lavery JA, Ananth CV, Vintzileos A. Placental implantation abnormalities and risk of preterm delivery: a systematic review and metaanalysis. Am J Obstet Gynecol. 2015;213:S78–S90. doi: 10.1016/j.ajog.2015.05.058 [DOI] [PubMed] [Google Scholar]
  • 18.Healy DL, Breheny S, Halliday J, Jaques A, Rushford D, Garrett C, et al. Prevalence and risk factors for obstetric haemorrhage in 6730 singleton births after assisted reproductive technology in Victoria Australia. Hum Reprod. 2010;25:265–274. doi: 10.1093/humrep/dep376 [DOI] [PubMed] [Google Scholar]
  • 19.Sazonova A, Källen K, Thurin-Kjellberg A, Wennerholm U-B, Bergh C. Factors affecting obstetric outcome of singletons born after IVF. Hum Reprod. 2011;26:2878–2886. doi: 10.1093/humrep/der241 [DOI] [PubMed] [Google Scholar]
  • 20.Fernando D, Halliday JL, Breheny S, Healy DL. Outcomes of singleton births after blastocyst versus nonblastocyst transfer in assisted reproductive technology. Fertil Steril. 2012;97:579–584. doi: 10.1016/j.fertnstert.2011.12.032 [DOI] [PubMed] [Google Scholar]
  • 21.Ginström Ernstad E, Bergh C, Khatibi A, Källén KBM, Westlander G, Nilsson S, et al. Neonatal and maternal outcome after blastocyst transfer: a population-based registry study. Am J Obstet Gynecol. 2016;214:378.e1–378.e10. doi: 10.1016/j.ajog.2015.12.040 [DOI] [PubMed] [Google Scholar]
  • 22.Ginström Ernstad E, Spangmose AL, Opdahl S, Henningsen A-KA, Romundstad LB, Tiitinen A, et al. Perinatal and maternal outcome after vitrification of blastocysts: a Nordic study in singletons from the CoNARTaS group. Hum Reprod. 2019;34:2282–2289. doi: 10.1093/humrep/dez212 [DOI] [PubMed] [Google Scholar]
  • 23.Spangmose AL, Ginström Ernstad E, Malchau S, Forman J, Tiitinen A, Gissler M, et al. Obstetric and perinatal risks in 4601 singletons and 884 twins conceived after fresh blastocyst transfers: a Nordic study from the CoNARTaS group. Hum Reprod. 2020;35:805–815. doi: 10.1093/humrep/deaa032 [DOI] [PubMed] [Google Scholar]
  • 24.Korosec S, Ban Frangez H, Verdenik I, Kladnik U, Kotar V, Virant-Klun I, et al. Singleton Pregnancy Outcomes after In Vitro Fertilization with Fresh or Frozen-Thawed Embryo Transfer and Incidence of Placenta Praevia. Biomed Res Int. 2014;2014:431797. doi: 10.1155/2014/431797 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Volodarsky-Perel A, Ton Nu TN, Buckett W, Machado-Gedeon A, Cui Y, Shaul J, et al. Effect of embryo stage at transfer on placental histopathology features in singleton live births resulting from fresh embryo transfers. Fertil Steril. 2021;115:673–682. doi: 10.1016/j.fertnstert.2020.06.017 [DOI] [PubMed] [Google Scholar]
  • 26.Cirillo F, Grilli L, Ronchetti C, Paladino I, Morenghi E, Busnelli A, et al. Retrospective comparison of pregnancy outcomes of fresh and frozen-warmed single blastocyst transfer: a 5-year single-center experience. J Assist Reprod Genet. 2022;39:201–209. doi: 10.1007/s10815-021-02362-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ishihara O, Araki R, Kuwahara A, Itakura A, Saito H, Adamson GD. Impact of frozen-thawed single-blastocyst transfer on maternal and neonatal outcome: an analysis of 277,042 single-embryo transfer cycles from 2008 to 2010 in Japan. Fertil Steril. 2014;101:128–133. doi: 10.1016/j.fertnstert.2013.09.025 [DOI] [PubMed] [Google Scholar]
  • 28.Wei D, Liu J-Y, Sun Y, Shi Y, Zhang B, Liu J-Q, et al. Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial. Lancet. 2019;393:1310–1318. doi: 10.1016/S0140-6736(18)32843-5 [DOI] [PubMed] [Google Scholar]
  • 29.Wang J, Liu Q, Deng B, Chen F, Liu X, Cheng J. Pregnancy outcomes of Chinese women undergoing IVF with embryonic cryopreservation as compared to natural conception. BMC Pregnancy Childbirth. 2021;21:39. doi: 10.1186/s12884-020-03486-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Carusi DA, Gopal D, Cabral HJ, Bormann CL, Racowsky C, Stern JE. A unique placenta previa risk factor profile for pregnancies conceived with assisted reproductive technology. Fertil Steril. 2022;118:894–903. doi: 10.1016/j.fertnstert.2022.08.013 [DOI] [PubMed] [Google Scholar]
  • 31.Frisell T. Invited Commentary: Sibling-Comparison Designs, Are They Worth the Effort? Am J Epidemiol. 2021;190:738–741. doi: 10.1093/aje/kwaa183 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Lawlor DA, Tilling K, Davey SG. Triangulation in aetiological epidemiology. Int J Epidemiol. 2016;45:1866–1886. doi: 10.1093/ije/dyw314 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Opdahl S, Henningsen A-KA, Bergh C, Gissler M, Romundstad LB, Petzold M, et al. Data Resource Profile: Committee of Nordic Assisted Reproductive Technology and Safety (CoNARTaS) cohort. Int J Epidemiol. 2020;49:365–366f. doi: 10.1093/ije/dyz228 [DOI] [PubMed] [Google Scholar]
  • 34.Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril. 2017;108:393–406. doi: 10.1016/j.fertnstert.2017.06.005 [DOI] [PubMed] [Google Scholar]
  • 35.Jansen CHJR, Kleinrouweler CE, van Leeuwen L, Ruiter L, Limpens J, van Wely M, et al. Final outcome of a second trimester low-positioned placenta: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2019;240:197–204. doi: 10.1016/j.ejogrb.2019.06.020 [DOI] [PubMed] [Google Scholar]
  • 36.Grønbeck L, Andersen LLT, Nørgaard LN. Placenta prævia og abnorm invasiv placenta. Dansk Selskab for Obstetrik og Gynækologi; 2017. Available from: https://www.dsog.dk/s/16112019_Placenta-prvia.pdf. [Google Scholar]
  • 37.Bolin K, Varli IH, Wollmann CL, Svanvik T, Skånes LT. SFOG-råd Handläggning av graviditet och förlossning vid placenta previa, vasa previa och invasiv placenta (accreta). Swedish Society of Obstetrics and Gynecology. 2020. Available from: https://www.sfog.se/media/337261/sfog-ra-d-placenta-previa-vasa-previa-och-invasiv-placenta-accreta-_slutgiltig_201215.pdf. [Google Scholar]
  • 38.Nyfløt LT, Pettersen S, Ebbing C, Almås I, Husby H, Aase TA, et al. Invasiv placenta, placenta previa og vasa previa. Norsk gynekologisk forening. 2020. Available from: https://www.legeforeningen.no/foreningsledd/fagmed/norsk-gynekologisk-forening/veiledere/veileder-i-fodselshjelp/invasiv-placenta-placenta-previa-og-vasa-previa/. [Google Scholar]
  • 39.Hernán MA, Robins JM. 3.3- Positivity. Causal inference: What If. Boca Raton: Chapman & Hall/CRC; 2020. p. 32–33. Available from: https://www.hsph.harvard.edu/miguel-hernan/wp-content/uploads/sites/1268/2024/01/hernanrobins_WhatIf_2jan24.pdf. [Google Scholar]
  • 40.Jenabi E, Salimi Z, Bashirian S, Khazaei S, Ayubi E. The risk factors associated with placenta previa: An umbrella review. Placenta. 2022;117:21–27. doi: 10.1016/j.placenta.2021.10.009 [DOI] [PubMed] [Google Scholar]
  • 41.Benaglia L, Candotti G, Papaleo E, Pagliardini L, Leonardi M, Reschini M, et al. Pregnancy outcome in women with endometriosis achieving pregnancy with IVF. Hum Reprod. 2016;31:2730–2736. doi: 10.1093/humrep/dew210 [DOI] [PubMed] [Google Scholar]
  • 42.Ibiebele I, Nippita T, Baber R, Torvaldsen S. Pregnancy outcomes in women with endometriosis and/or ART use: a population-based cohort study. Hum Reprod. 2022;37:2350–2358. doi: 10.1093/humrep/deac186 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gómez-Pereira E, Burgos J, Mendoza R, Pérez-Ruiz I, Olaso F, García D, et al. Endometriosis Increases the Risk of Placenta Previa in Both IVF Pregnancies and the General Obstetric Population. Reprod Sci. 2023;30:854–864. doi: 10.1007/s43032-022-01054-2 [DOI] [PubMed] [Google Scholar]
  • 44.Romundstad LB, Romundstad PR, Sunde A, von Düring V, Skjaerven R, Vatten LJ. Increased risk of placenta previa in pregnancies following IVF/ICSI; a comparison of ART and non-ART pregnancies in the same mother. Hum Reprod. 2006;21:2353–2358. doi: 10.1093/humrep/del153 [DOI] [PubMed] [Google Scholar]
  • 45.Baba K, Ishihara O, Hayashi N, Saitoh M, Taya J, Kinoshita K. Where does the embryo implant after embryo transfer in humans? Fertil Steril. 2000;73:123–125. doi: 10.1016/s0015-0282(99)00454-9 [DOI] [PubMed] [Google Scholar]
  • 46.Knutzen V, Stratton CJ, Sher G, McNamee PI, Huang TT, Soto-Albors C. Mock embryo transfer in early luteal phase, the cycle before in vitro fertilization and embryo transfer: a descriptive study. Fertil Steril. 1992;57:156–162. doi: 10.1016/S0015-0282(16)54793-1 [DOI] [PubMed] [Google Scholar]
  • 47.Rombauts L, Motteram C, Berkowitz E, Fernando S. Risk of placenta praevia is linked to endometrial thickness in a retrospective cohort study of 4537 singleton assisted reproduction technology births. Hum Reprod. 2014;29:2787–2793. doi: 10.1093/humrep/deu240 [DOI] [PubMed] [Google Scholar]
  • 48.Kalakota NR, George LC, Morelli SS, Douglas NC, Babwah AV. Towards an Improved Understanding of the Effects of Elevated Progesterone Levels on Human Endometrial Receptivity and Oocyte/Embryo Quality during Assisted Reproductive Technologies. Cells. 2022;11:1405. doi: 10.3390/cells11091405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Bourgain C, Ubaldi F, Tavaniotou A, Smitz J, Van Steirteghem AC, Devroey P. Endometrial hormone receptors and proliferation index in the periovulatory phase of stimulated embryo transfer cycles in comparison with natural cycles and relation to clinical pregnancy outcome. Fertil Steril. 2002;78:237–244. doi: 10.1016/s0015-0282(02)03228-4 [DOI] [PubMed] [Google Scholar]
  • 50.Oron G, Hiersch L, Rona S, Prag-Rosenberg R, Sapir O, Tuttnauer-Hamburger M, et al. Endometrial thickness of less than 7.5 mm is associated with obstetric complications in fresh IVF cycles: a retrospective cohort study. Reprod Biomed Online. 2018;37:341–348. doi: 10.1016/j.rbmo.2018.05.013 [DOI] [PubMed] [Google Scholar]
  • 51.Guo Z, Xu X, Zhang L, Zhang L, Yan L, Ma J. Endometrial thickness is associated with incidence of small-for-gestational-age infants in fresh in vitro fertilization–intracytoplasmic sperm injection and embryo transfer cycles. Fertil Steril. 2020;113:745–752. doi: 10.1016/j.fertnstert.2019.12.014 [DOI] [PubMed] [Google Scholar]
  • 52.Jing S, Li X, Zhang S, Gong F, Lu G, Lin G. The risk of placenta previa and cesarean section associated with a thin endometrial thickness: a retrospective study of 5251 singleton births during frozen embryo transfer in China. Arch Gynecol Obstet. 2019;300:1227–1237. doi: 10.1007/s00404-019-05295-6 [DOI] [PubMed] [Google Scholar]
  • 53.Zhang X, Liang L, Hu Y, Zhang Z, Wu Y, Zhang X, et al. A thinner endometrium is associated with lower newborn birth weight during in vitro fertilization–frozen-embryo transfer: a cohort study. Gynecol Endocrinol. 2023;39:2217269. doi: 10.1080/09513590.2023.2217269 [DOI] [PubMed] [Google Scholar]
  • 54.Zhu H, Liu L, Yang L, Xue Y, Tong X, Jiang L, et al. The effect of progesterone level prior to oocyte retrieval on the numbers of oocytes retrieved and embryo quality in IVF treatment cycles: an analysis of 2,978 cycles. J Assist Reprod Genet. 2014;31:1183–1187. doi: 10.1007/s10815-014-0291-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Magnusson Å, Wennerholm U-B, Källén K, Petzold M, Thurin- Kjellberg A, Bergh C. The association between the number of oocytes retrieved for IVF, perinatal outcome and obstetric complications. Hum Reprod. 2018;33:1939–1947. doi: 10.1093/humrep/dey266 [DOI] [PubMed] [Google Scholar]
  • 56.Rabe-Hesketh S, Skrondal A. 10.14.1- Conditional logistic regression. Multilevel and longitudinal modeling using Stata- Volume II: Categorical Responses, Counts, and Survival- Third Edition. STATA press; 2012. p. 557–559. [Google Scholar]
  • 57.Bi S, Zhang L, Wang Z, Chen J, Tang J, Gong J, et al. Effect of types of placenta previa on maternal and neonatal outcomes: a 10-year retrospective cohort study. Arch Gynecol Obstet. 2021;304:65–72. doi: 10.1007/s00404-020-05912-9 [DOI] [PubMed] [Google Scholar]
  • 58.Jansen CHJR, van Dijk CE, Kleinrouweler CE, Holzscherer JJ, Smits AC, Limpens JCEJM, et al. Risk of preterm birth for placenta previa or low-lying placenta and possible preventive interventions: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:921220. doi: 10.3389/fendo.2022.921220 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Jauniaux E, Alfirevic Z, Bhide A, Belfort M, Burton G, Collins S, et al. Placenta Praevia and Placenta Accreta: Diagnosis and Management. BJOG. 2019;126:e1–e48. doi: 10.1111/1471-0528.15306 [DOI] [PubMed] [Google Scholar]
  • 60.Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim J-L, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:1–16. doi: 10.1186/1471-2458-11-450 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Penzias A, Bendikson K, Falcone T, Hansen K, Hill M, Jindal S, et al. Evidence-based treatments for couples with unexplained infertility: a guideline. Fertil Steril. 2020;113:305–322. doi: 10.1016/j.fertnstert.2019.10.014 [DOI] [PubMed] [Google Scholar]
  • 62.Matsuzaki S, Nagase Y, Ueda Y, Kakuda M, Maeda M, Matsuzaki S, et al. Placenta Previa Complicated with Endometriosis: Contemporary Clinical Management, Molecular Mechanisms, and Future Research Opportunities. Biomedicine. 2021;9:1536. doi: 10.3390/biomedicines9111536 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Velez MP, Bougie O, Bahta L, Pudwell J, Griffiths R, Li W, et al. Mode of conception in patients with endometriosis and adverse pregnancy outcomes: a population-based cohort study. Fertil Steril. 2022;118:1090–1099. doi: 10.1016/j.fertnstert.2022.09.015 [DOI] [PubMed] [Google Scholar]
  • 64.Q-IVF. National reports from Q-IVF (Nationellt kvalitetsregister för assisterad befruktning). 2023. [cited 12 Dec 2024]. Available from: https://www.medscinet.com/qivf/arsrapporter.aspx. [Google Scholar]

Decision Letter 0

Louise Gaynor-Brook

14 Aug 2024

Dear Dr Landsverk,

Thank you for submitting your manuscript entitled "Risk of placenta previa in assisted reproductive technology: A Nordic population study with sibling analyses" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Aug 16 2024 11:59PM.

Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email me at lgaynor@plos.org if you have any queries relating to your submission.

Kind regards,

Louise Gaynor-Brook, MBBS PhD

Senior Editor

PLOS Medicine

Decision Letter 1

Louise Gaynor-Brook

28 Nov 2024

Dear Dr Landsverk,

Many thanks for submitting your manuscript "Risk of placenta previa in assisted reproductive technology: A Nordic population study with sibling analyses" (PMEDICINE-D-24-02651R1) to PLOS Medicine. The paper has been reviewed by subject experts and a statistician; their comments are included below and can also be accessed here: [LINK]

After discussing the paper with the editorial team and an academic editor with relevant expertise, I'm pleased to invite you to revise the paper in response to the reviewers' comments. We plan to send the revised paper to some or all of the original reviewers, and we cannot provide any guarantees at this stage regarding publication.

When you upload your revision, please include a point-by-point response that addresses all of the reviewer and editorial points, indicating the changes made in the manuscript and either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please also be sure to check the general editorial comments at the end of this letter and include these in your point-by-point response. When you resubmit your paper, please include a clean version of the paper as the main article file and a version with changes tracked as a marked-up manuscript. It may also be helpful to check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper.

We ask that you submit your revision by Dec 19 2024 11:59PM. However, if this deadline is not feasible, please contact me by email, and we can discuss a suitable alternative.

Don't hesitate to contact me directly with any questions (lgaynor@plos.org).

Best regards,

Louise

Louise Gaynor-Brook, MBBS PhD

Senior Editor

PLOS Medicine

lgaynor@plos.org

-----------------------------------------------------------

Comments from the academic editor:

I agree that the fact the data goes back a long way is a significant limitation: this, and the potential impact of changing ART techniques, could be discussed in more depth. I am not convinced of the need for a country stratified analysis.

-----------------------------------------------------------

Comments from the reviewers:

Reviewer #1: In this paper, the authors conduct a retrospective registry study examining the relative odds of placenta previa in pregnancies using assisted retroductive technology (ART) vs. natural conception (NC). Major strengths of this study include the large sample size derived from a set of high quality national registries, which allows for the ability/power to examine specific sub-populations and sensitivity comparisons, and the use of a within-mother analysis in order to reduce heterogeneity due to mother-specific confounders. In general, we commend the authors on this well conducted study. A few suggestions are provided below.

I actually thought that Figure 2 regarding the nine potential combinations of first vs. second delivery modality deserved much more discussion than was provided in the manuscript. Some important patterns: we see lower predicted risk of placenta previa between the first delivery and second delivery when the first delivery is fresh-ET /except/ when the second delivery is also fresh-ET. Additionally, the magnitude of the increased predicted risk for first-delivery-NC pairs seems to vary greatly depending on the modality of the second delivery. These "differences in differences" so to speak are potentially of clinical interest, though they are only observational associations found in the data.

Throughout the manuscript, there is occasional use of unsubstantiated causal language, which is not acceptable given the observational nature of the study (e.g., line 233-234: "ART increased the risk" as opposed to "ART was associated with increased risk beyond..."). One major area where we believe this language should definitely be changed is in line 71-72 ("assisted reproductive technology contributed to the increased risk"), which is a fully causal statement that was not supported by the analysis (the authors did not conduct a causal inference-informed approach). Despite the sibling design and the within-mother matching, and the comments on lines 288-290, such statements are still not appropriate. For instance, there still may remain potential unmeasured confounding due to time-varying factors between pregnancies. Thus, in the conclusion lines 319-320, it is also inappropriate to state that the higher observed risk is "attributed" to a combination of treatment and maternal factors (even if there is a biologically plausible explanation). To be most appropriate, we would prefer language such as "the highest risk of placenta previa after ART is associated with both...". For some more minor examples of problematic causal language, it may be more appropriate in lines 69-70 to state "The largest difference in risk was seen" as opposed to "The highest risk increase," as the latter (current) language implies a causal relationship. Along these lines, it may be worth stating that the confounders referred to in lines 157-159 are /previously known confounders/ (with the implication being that there may always be unmeasured confounders, which will certainly be the case in large registry studies such as this one, e.g., environmental exposures, etc.

Although the authors mention that a country-stratified analysis was not performed, it still may be of interest, perhaps due to potentially different medical practices or circumstances between (admittedly very similar) countries; even in a simple additionally sensitivity analysis that simply incorporated country as a categorical variable to be adjusted for, is there truly no evidence of difference across country lines? The inclusion of this variable is unlikely to affect inferential results if the relationship is truly null given the large sample size; it struck me as a strange modeling choice not to use data so immediately available and that may be potentially worth exploring. On a somewhat related note, I appreciated your discussion of the generalizability of the study; I would have preferred if you were even more explicit in mentioning that Nordic countries may not have populations which are comparable to those of other countries. For instance, you do discuss the difference in overall rate of placenta previa with respect to Ishihara et al., but it would have been stronger to explicitly mention this potential drawback (i.e., generalizing to other populations) as well.

Finally, as a very small curiosity of mine, I wonder whether parity was included as a linear or categorical variable in your models when adjusting for them. Some additional clarity there would be appreciated.

In any case, a well-written, clear, and well-conducted study. It is likely to be of great interest to epidemiologists and practitioners.

Reviewer #2: This is an excellent study performed by a highly experienced group of investigators, using a combined Nordic dataset that has been used previously. The study question was whether ART increases the risk for placenta previa. The authors evaluate this in a full population of ART and Naturally Conceived (NC) pregnancies as well as sequential pregnancies within the same woman. They analyze over 5 million pregnancies in 3 million mothers. They find that ART increases the rate of placenta previa and that specific ART techniques including fresh transfer (compared to frozen) and blastocyst transfer (compared to cleavage stage) showed the highest rates. In addition, specific infertility diagnoses were investigated and showed that endometriosis patients had a higher rate of placenta previa.

The data analysis in the paper is exhaustive. The tables and figures are appropriate, and the reference list appears comprehensive.

I had one question about the study population as described in Methods. It was not clear to me (perhaps I missed it), what was done with more than 2 pregnancies per woman. I assume that all pregnancies were included in the "Eligible sample". For the within woman comparisons, were just the first 2 pregnancies compared or was pregnancy 1 compared with pregnancy 2 and then pregnancy 2 compared with pregnancy 3? This should be clarified. Also, was any calculation done to adjust for multiple pregnancies to the same woman in the overall analysis?

I think that the authors should add the limitation that the study period spanned the years 1988-2015 which means it includes very old cases and that it does not include the most recent cases. While year was adjusted for, there have been many changes to ART protocols over the years that could make a difference.

Reviewer #3: Congratulations on a very substantial body of work establishing that it is likely that presented previous is more common in IRT with variations dependent on the cause of infertility the staging of embryo transfer and particular interest presence of endometriosis. As much as I appreciate the statistical value of odds ratios, as a clinician the raw numbers are probably more relevant when counselling patients. I would ask that the the final sentence in the conclusion is unnecessary. It perhaps should be

From a clinician's perspective, the increased risks of placenta praevia, which is rarely a lifethreatening complication, are unlikely to change the chosen ART treatment approach. The primary goal of maximum pregnancy success will override these statistical findings. section rates but against a background of high rates after ART , the extra numbers will be relatively small .

Any attachments provided with reviews can be seen via the following link: [LINK]

---------------------------------------------------------

General editorial requests:

(Note: not all will apply to your paper, but please check each item carefully)

* We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. Please do not add or remove authors without first discussing this with the handling editor. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

* Please upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

* Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information (web or email address) for obtaining the data. Please note that a study author cannot be the contact person for the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

* We expect all researchers with submissions to PLOS in which author-generated code underpins the findings in the manuscript to make all author-generated code available without restrictions upon publication of the work. In cases where code is central to the manuscript, we may require the code to be made available as a condition of publication. Authors are responsible for ensuring that the code is reusable and well documented. Please make any custom code available, either as part of your data deposition or as a supplementary file. Please add a sentence to your data availability statement regarding any code used in the study, e.g. "The code used in the analysis is available from Github [URL] and archived in Zenodo [DOI link]" Please review our guidelines at https://journals.plos.org/plosmedicine/s/materials-software-and-code-sharing and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse. Because Github depositions can be readily changed or deleted, we encourage you to make a permanent DOI'd copy (e.g. in Zenodo) and provide the URL.

FORMATTING - GENERAL

* Abstract: Please structure your abstract using the PLOS Medicine headings (Background, Methods and Findings, Conclusions). Please combine the Methods and Findings sections into one section.

* At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Ideally each sub-heading should contain 2-3 single sentence, concise bullet points containing the most salient points from your study. In the final bullet point of 'What Do These Findings Mean?', please include the main limitations of the study in non-technical language. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary.

* Please express the main results with 95% CIs as well as p values. When reporting p values please report as p<0.001 and where higher as the exact p value p=0.002, for example. Throughout, suggest reporting statistical information as follows to improve clarity for the reader "22% (95% CI [13%,28%]; p</=)". Please be sure to define all numerical values at first use.

* Please include page numbers and line numbers in the manuscript file. Use continuous line numbers (do not restart the numbering on each page).

* Please cite the reference numbers in square brackets. Citations should precede punctuation.

FIGURES AND TABLES

* Please provide titles and legends for all figures and tables (including those in Supporting Information files).

* Please define all abbreviations used in each figure/table (including those in Supporting Information files).

* Please consider avoiding the use of red and green in order to make your figure more accessible to those with color blindness.

SUPPLEMENTARY MATERIAL

* Please note that supplementary material will be posted as supplied by the authors. Therefore, please amend it according to the relevant comments outlined here.

* Please cite your Supporting Information as outlined here: https://journals.plos.org/plosmedicine/s/supporting-information

REFERENCES

* PLOS uses the numbered citation (citation-sequence) method and first six authors, et al.

* Please ensure that journal name abbreviations match those found in the National Center for Biotechnology Information (NCBI) databases (http://www.ncbi.nlm.nih.gov/nlmcatalog/journals), and are appropriately formatted and capitalised.

* Where website addresses are cited, please include the complete URL and specify the date of access (e.g. [accessed: 12/06/2023]).

* Please also see https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references for further details on reference formatting.

STUDY TYPE-SPECIFIC REQUESTS: OBSERVATIONAL STUDIES

* Abstract: Please include the study design, population and setting, number of participants, years during which the study took place (enrollment and follow up), length of follow up, and main outcome measures.

* Please ensure that the study is reported according to the RECORD guideline (available from https://www.record-statement.org) and include the completed checklist as Supporting Information. Please add the following statement, or similar, to the Methods: "This study is reported as per the Reporting of Studies Conducted using Observational Routinely-Collected Data (RECORD) guideline (S1 Checklist)." When completing the checklist, please use section and paragraph numbers, rather than page numbers.

* For all observational studies, in the manuscript text, please indicate: (1) the specific hypotheses you intended to test, (2) the analytical methods by which you planned to test them, (3) the analyses you actually performed, and (4) when reported analyses differ from those that were planned, transparent explanations for differences that affect the reliability of the study's results. If a reported analysis was performed based on an interesting but unanticipated pattern in the data, please be clear that the analysis was data driven.

* Please state in the Methods section whether the study had a prospective protocol or analysis plan. If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant document(s) with your revised manuscript as a Supporting Information file to be published alongside your study and cite it in the Methods section. A legend for this file should be included at the end of your manuscript. If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place. Changes in the analysis, including those made in response to peer review comments, should be identified as such in the Methods section of the paper, with rationale.

Decision Letter 2

Louise Gaynor-Brook

10 Jan 2025

Dear Dr. Landsverk,

Thank you very much for re-submitting your manuscript "Risk of placenta previa in assisted reproductive technology: A Nordic population study with sibling analyses" (PMEDICINE-D-24-02651R2) for review by PLOS Medicine. I am writing on behalf of my colleague Louise Gaynor Brook, who is away from the office.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by one of the original reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email and minor edits are in the attached word document. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.  

We look forward to receiving the revised manuscript by Jan 17 2025 11:59PM.   

Sincerely,

Alison Farrell PhD

Senior Editor 

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

Please note edits in the attached file.

Please be sure to acknowledge unmeasured confounders in your discussion of study limitations.

Please reiterate that while country-specific analyses were not feasible in all instances due to missing data, that country was included as a categorical covariate in analyses.

Please state early in the text that you followed a prespecified statistical analysis plan.

If new code was generated in this study, please deposit in GitHub and provide the url.

Please address the following issues:

Data availability statement is missing. For each data source used in your study:

a) If the data are freely or publicly available, note this and state the location of the data: within the paper, in Supporting Information files, or in a public repository (include the DOI or accession number).

b) If the data are owned by a third party but freely available upon request, please note this and state the owner of the data set and contact information for data requests (web or email address). Note that a study author cannot be the contact person for the data.

c) If the data are not freely available, please describe briefly the ethical, legal, or contractual restriction that prevents you from sharing it. Please also include an appropriate contact (web or email address) for inquiries (again, this cannot be a study author).

Author contribution statement is missing.

Acknowledgements section is blank (acknowledge participants whose data are used?)

Clarify use of data--ethics/consent waived? Clarify how identities are protected given that you have used national identity numbers.

GATHER statement: If appropriate, please report your data according to GATHER and enclose a completed GATHER checklist as a supplementary document. See http://gather-statement.org/ In the checklist please include sufficient text excerpted from the manuscript to explain how you accomplished all applicable items.

Competing Interests Statement: * All authors must declare their relevant competing interests per the PLOS policy, which can be seen here: https://journals.plos.org/plosmedicine/s/competing-interests For authors with ties to industry, please indicate whether any of the interests has a financial stake in the results of the current study.

Comments from Reviewers:

Reviewer #1: Thank you for comprehensively addressing the points raised in my original review. We are satisfied with the changes and have no further comments.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Attachment

Submitted filename: Landsverk_edits.docx

pmed.1004536.s011.docx (227.1KB, docx)

Decision Letter 3

Louise Gaynor-Brook

20 Jan 2025

Dear Dr Landsverk, 

On behalf of my colleagues and the Academic Editor, Jenny Myers, I am pleased to inform you that we have agreed to publish your manuscript "Risk of placenta previa in assisted reproductive technology: A Nordic population study with sibling analyses" (PMEDICINE-D-24-02651R3) in PLOS Medicine.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.

In the meantime, please log into Editorial Manager at http://www.editorialmanager.com/pmedicine/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. 

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with medicinepress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper. 

Sincerely, 

Alison Farrell, PhD 

Senior Editor 

PLOS Medicine

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. The RECORD statement—checklist of items, extended from the STROBE statement that should be reported in observational studies using routinely collected health data.

    (DOCX)

    pmed.1004536.s001.docx (34.3KB, docx)
    S1 Table. Data sources and registration practice for placenta previa in the Nordic countries during the study period.

    (DOCX)

    pmed.1004536.s002.docx (20.8KB, docx)
    S2 Table. Data sources and registration practice for infertility factors in the Nordic countries during the study period.

    (DOCX)

    pmed.1004536.s003.docx (21.9KB, docx)
    S3 Table. ICD codes used for identification of infertility factors in the Nordic countries during the study period.

    (DOCX)

    pmed.1004536.s004.docx (20.6KB, docx)
    S4 Table. Observed risk and adjusted odds ratio of placenta previa in second pregnancy according to conception method and cesarean section in first pregnancy in sample 1.

    (DOCX)

    pmed.1004536.s005.docx (23.2KB, docx)
    S5 Table. Observed risk and adjusted odds ratio of placenta previa in second pregnancy according to conception method and placenta previa in first pregnancy in sample 1.

    (DOCX)

    pmed.1004536.s006.docx (23.2KB, docx)
    S6 Table. Description of pregnancies with and without placenta previa according to conception method and plurality in sample 1.

    (DOCX)

    pmed.1004536.s007.docx (25.9KB, docx)
    S1 Text. More detailed description of sensitivity analyses.

    (DOCX)

    pmed.1004536.s008.docx (21.8KB, docx)
    S1 Study Protocol. Risk of placenta previa in assisted reproductive technology: A Nordic registry-based population study with within-sibship analyses.

    (PDF)

    pmed.1004536.s009.pdf (272.4KB, pdf)
    Attachment

    Submitted filename: Response_to_reviewers (2).docx

    pmed.1004536.s010.docx (40.1KB, docx)
    Attachment

    Submitted filename: Landsverk_edits.docx

    pmed.1004536.s011.docx (227.1KB, docx)
    Attachment

    Submitted filename: Response_to_reviewers (2).docx

    pmed.1004536.s012.docx (40.1KB, docx)

    Data Availability Statement

    Data cannot be shared publicly owing to restrictions by law. Data are available from the CoNARTaS server at Statistics Denmark, after approval by the Ethics Committees and registry keeping authorities in each country, as described in the following publication: Opdahl S, Henningsen AA, Bergh C, Gissler M, Romundstad LB, Petzold M, Tiitinen A, Wennerholm UB, Pinborg AB. Data Resource Profile: Committee of Nordic Assisted Reproductive Technology and Safety (CoNARTaS) cohort. Int J Epidemiol. 2020 Apr 1;49(2):365-366f. doi: 10.1093/ije/dyz228. Contact information for Statistics Denmark: Division of Research Services, Statistics Denmark, Sejrøgade 11, DK-2100, Copenhagen, Denmark. E-mail:forskningsservice@dst.dk. Phone: +45 39 17 31 30.


    Articles from PLOS Medicine are provided here courtesy of PLOS

    RESOURCES